• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Janssen submits sNDA to FDA seeking new indication for INVOKANA

Janssen submits sNDA to FDA seeking new indication for INVOKANA

October 3, 2017
CenterWatch Staff

Janssen Research & Development has submitted a supplemental New Drug Application (sNDA) to the FDA seeking a new indication for INVOKANA (canagliflozin) to reduce the risk of major adverse cardiovascular events (MACE), composed of cardiovascular (CV) death, myocardial infarction and stroke, in adults with type 2 diabetes who have established CV disease or are at risk for CV disease.

The application also applies to INVOKANA's fixed-dose combinations, INVOKAMET and INVOKAMET XR, and is based on findings from the landmark CANVAS clinical trial program, which were presented at a special symposium at the American Diabetes Association 77th Scientific Sessions in June 2017 and simultaneously published in The New England Journal of Medicine.

"People with type 2 diabetes have a substantially increased risk of developing cardiovascular disease, and it's encouraging that we now have data to show INVOKANA® may help address this challenge," said James F. List, M.D., Ph.D., Global Therapeutic Area Head, Cardiovascular & Metabolism, Janssen. "INVOKANA has shown a clear benefit in reducing cardiovascular risk in adults with type 2 diabetes and we look forward to working with FDA as it reviews our filing."

Of the approximately 30 million people living with diabetes in the U.S., 90 to 95% have type 2 diabetes, and are two to four times more likely to die from heart disease than those without diabetes.

The sNDA is based on data from the CANVAS Program, which evaluated the CV safety and efficacy of canagliflozin relative to placebo in adults with type 2 diabetes who had either established CV disease or were at risk for CV disease, which was defined as having two or more CV risk factors. The primary endpoint was defined as MACE, composed of CV death, nonfatal myocardial infarction and nonfatal stroke. The CANVAS Program is composed of two similar clinical trials, CANVAS and CANVAS-R, and evaluated more than 10,000 patients for an average of 188 weeks, including 296 weeks in CANVAS and 108 weeks in CANVAS-R.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing